New treatment capable of reversing resistance to angiogenesis

Master Professor of Molecular Oncology, Dr. Miguel Quintela, and his team have published an interesting study in Cell Report about a new mechanism to slow the progression of breast cancer through the combination of an angiogenesis inhibitor with an antidiabetic agent.
Anti-angiogenic drugs are commonly used for treating various cancers, however most patients with epithelial tumors develop resistance to this treatment. This article focuses on the study of the mechanisms induced by the tyrosine kinase inhibitor approved by the FDA and EMEA, nintedanib, l Jan involved development of resistance to tackle this problem.
These studies have uncovered as the administration of nintedanib triggers a change in cell metabolism which triggers consumption amount 20 glucose times higher than normal cells. These observations led to the antiangiogenic drug combination therapy with a mitochondrial blocker, fenformina, in murine tumor models of breast, observing an inhibition to 92% tumor growth.
These interesting results are allowing the design of new clinical trials to study the effect on breast cancer patients combined treatment for both agents.